GlaxoSmithKline (LON:GSK) posted its earnings results on Wednesday. The company reported GBX 52.70 ($0.70) earnings per share for the quarter, Bloomberg Earnings reports. GlaxoSmithKline had a return on equity of 348.10% and a net margin of 9.36%.
GlaxoSmithKline traded up GBX 17.20 ($0.23), hitting GBX 1,553.40 ($20.56), during trading on Friday, according to Marketbeat Ratings. 8,539,369 shares of the stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($16.35) and a 1-year high of GBX 1,724.50 ($22.83).
The company also recently declared a dividend, which will be paid on Thursday, October 11th. Shareholders of record on Thursday, August 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 9th.
Several equities research analysts recently weighed in on the company. Berenberg Bank boosted their target price on GlaxoSmithKline from GBX 1,780 ($23.56) to GBX 1,790 ($23.69) and gave the stock a “buy” rating in a research note on Wednesday, April 25th. Credit Suisse Group set a GBX 1,450 ($19.19) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Monday, July 16th. Deutsche Bank set a GBX 1,525 ($20.19) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Monday, July 9th. Cfra set a GBX 1,550 ($20.52) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. set a GBX 1,550 ($20.52) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday, July 10th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 1,533.82 ($20.30).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Dividend
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.